×

Rosetta Genomics Announces New Patent Allowance and Provides Intellectual Property Update New Notice of Allowance is for U.S. Patent Related to hsa-miR-451

REHOVOT, Israel & PHILADELPHIA, May 10, 2010 (BUSINESS WIRE) -- --Brings U.S. Patent Estate to 10 Issued and 10 Allowed Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview(TM) mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

With this new patent allowance, Rosetta's intellectual property portfolio includes 10 issued U.S. patents, 10 U.S. allowed patent applications and one allowed patent application in Australia. Rosetta Genomics maintains a robust intellectual property strategy to protect its leadership position in microRNA technology and has 95 patent applications, 35 of them filed in the U.S. and 60 around the rest of the world.

"This recent notice of allowance of miR-451 is yet another important building block in our constantly growing comprehensive IP estate, as we continue to harness the power of microRNAs," said Kenneth A. Berlin, President and CEO of Rosetta Genomics. "We view our leading position in microRNA IP as one of Rosetta Genomics' core strengths, and we are continuously leveraging this strength to advance our overall business operations. microRNAs are well established as sensitive biomarkers, potential drug targets, as well as key players in a wide range of cellular processes, and we are proud that our early discoveries in this field are now materializing into a robust portfolio of issued and allowed patents." About microRNAs MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced.

To learn more about microRNAs, please visit www.rosettagenomics.com .

About miRview(TM) Products miRview(TM) products are a series of microRNA-based diagnostic tests developed by Rosetta Genomics. miRview(TM) mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP) patients.

miRview(TM) squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. miRview(TM) meso diagnoses mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRview(TM) tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. The company's tests are now being offered through distributors around the globe. For more information, please visit www.mirviewdx.com .

About Rosetta Genomics Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics.

Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company's first three microRNA-based tests, miRview(TM) squamous, miRview(TM) mets and miRview(TM) meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal's Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com .

Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Rosetta's intellectual property portfolio, and its potential to provide protection to Rosetta's research and development efforts, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

SOURCE: Rosetta Genomics, Ltd.

CONTACT: Media Contact: Rosetta Genomics, Ltd. Ron Kamienchick, 215-382-9000, ext. 318 investors@rosettagenomics.com or Investors Contacts: Lippert/Heilshorn & Associates Anne Marie Fields, 212-838-3777 x6604 afields@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com Copyright Business Wire 2010 -0- KEYWORD: United States

Israel

North America

Middle East

Pennsylvania INDUSTRY KEYWORD: Health

Biotechnology

Genetics

Oncology

Other Health

General Health SUBJECT CODE: Product/Service